Search

Search Constraints

You searched for: Author/Creator Ahn, J.S.

Search Results

2. 3101 Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small-cell lung cancer (NSCLC). (September 2015)

3. 57O Randomized double-blind phase II trial (PERLA) of dostarlimab (dostar) + chemotherapy (CT) vs pembrolizumab (pembro) + CT in metastatic non-squamous NSCLC: Primary results. (December 2022)

5. 59 INFERIOR LONG-TERM OUTCOME OF FRONT-LINE HMA COMPARED TO SUPPORTIVE CARE IN PATIENTS WITH LOWER RISK MDS: PROPENSITY SCORE MATCHED ANALYSIS. (April 2015)

6. 85 SUPERIOR LONG-TERM OUTCOMES OF ALLOGENEIC HCT IN RESPONSE COMPARED TO RELAPSED OR REFRACTORY AFTER HMA FOR PATIENTS WITH LOWER RISK MDS. (April 2015)